Rami Manochakian

Thoracic medical oncologist at the Mayo Clinic and expert in lung cancer clinical trials and targeted therapies, invited to review ESMO 2025 practice-changing lung cancer data.

Best podcasts with Rami Manochakian

Ranked by the Snipd community

Nov 6, 2025 • 25min

Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1

Dr. Rami Manochakian, a thoracic oncologist from the Mayo Clinic, shares groundbreaking insights from ESMO 2025 on lung cancer. He highlights the significance of the MDT-BRIDGE trial, which showcases a multidisciplinary approach for non-small cell lung cancer. The conversation dives into the FLAURA2 study, showing survival benefits of osimertinib with chemotherapy. Plus, he introduces promising HER2-targeted therapies like Zongertinib and Sevabertinib, emphasizing the need for upfront NGS testing to personalize treatment strategies.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app